본문 바로가기

National OncoVenture (NOV)

  • Home
  • Research Institute
  • National OncoVenture (NOV)

The National Cancer Center (NCC) of Korea launched a new government funded R&D program, called "National OncoVenture" (formerly known as “Bridging and Development” Program) for cancer drug development in 2011 to bridge the gap between discovery and development in drug development in Korea. Main objective of National OncoVenture (NOV) is to co-develop new anti-cancer drug candidates from the original inventors in academia, government-funded institutes and industry by a group of drug development experts in NOV carrying out preclinical and early clinical trials. The National Oncoventure aims to develop 4 Global Drug Candidates that will have completed phase 2 human clinical trials by 2021.

Vision : Global Cancer Drug Development, Goal : Develop 4 Global Drug Candidates with PII completion by 2021, Expert Network <> National Onco Venture Drug value Global drug Candidate <> Outsourcing CRO, CMOs, Drug Candidate > National Onco Venture Drug value Global drug Candidate > License Out

NOV link